Resistance to Targeted Therapies Against Adult Brain Cancers (Resistance to Targeted Anti-Cancer Therapeutics)
Resistance to Targeted Therapies Against Adult Brain Cancers (Resistance to Targeted Anti-Cancer Therapeutics) by Amanda Tivnan
English | 18 Dec. 2016 | ISBN: 331946504X | 278 Pages | PDF | 6.11 MB
English | 18 Dec. 2016 | ISBN: 331946504X | 278 Pages | PDF | 6.11 MB
This volume will bring together a review of research being carried out by international experts in this field, detailing treatment and research approaches in several forms of malignant brain tumors. These include glioblastoma (GBM), a highly aggressive and fatal form of astrocytoma which accounts for 80% of newly diagnosed brain tumor patients per year, and meningioma, of which 10% are malignant and extremely resistant to targeted therapies. The volume will also include a discussion of methods to overcome blood-brain barrier exclusion for more efficient targeted drug delivery in all forms of brain cancer treatment. The volume will include information on the repurposing of drugs in an attempt to circumvent drug resistance, use of small molecule inhibitors in GBM treatment, mechanisms of secondary brain metastasis, drug resistance, and state-of-the-art imaging of targeted therapies